Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLRMT | O00411 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.32 |
| ▸ | BTN3A1 | O00481 | 4/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26275736 | 1.00 | POLRMT (0.39) | POLRMTCYP3A4CYP2C9DOT1LBTN3A1 | |
| SCHEMBL26276058 | 1.00 | POLRMT (0.39) | POLRMTCYP3A4CYP2C9DOT1LBTN3A1 | |
| SCHEMBL26276164 | 1.00 | POLRMT (0.39) | POLRMTCYP3A4CYP2C9DOT1LBTN3A1 | |
| SCHEMBL26276590 | 1.00 | POLRMT (0.39) | POLRMTCYP3A4CYP2C9DOT1LBTN3A1 | |
| SCHEMBL23802569 | 1.00 | POLRMT (0.39) | POLRMTCYP3A4CYP2C9DOT1LBTN3A1 | |
| SCHEMBL26276061 | 1.00 | POLRMT (0.39) | POLRMTCYP3A4CYP2C9DOT1LBTN3A1 | |
| SCHEMBL26276060 | 1.00 | POLRMT (0.39) | POLRMTCYP3A4CYP2C9DOT1LBTN3A1 | |
| SCHEMBL26276158 | 1.00 | POLRMT (0.39) | POLRMTCYP3A4CYP2C9DOT1LBTN3A1 | |
| SCHEMBL26276162 | 1.00 | POLRMT (0.39) | POLRMTCYP3A4CYP2C9DOT1LBTN3A1 | |
| SCHEMBL26275992 | 0.99 | POLRMT (0.40) | POLRMTCYP3A4CYP2C9DOT1LBTN3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4107164-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12264173-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20250034186-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2025-01-30 | — | — | US | disclosed |
| US-12054507-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-20240174704-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2024-05-30 | — | — | US | disclosed |
| US-11767337-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767337-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
| EP-4107164-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-28 | — | — | EP | disclosed |
| EP-4106877-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-28 | — | — | EP | disclosed |
| US-20220356196-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2022-11-10 | — | — | US | disclosed |
| US-20210284670-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2021-09-16 | — | — | US | disclosed |
| US-20210284670-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2021-09-16 | — | — | US | disclosed |
| US-20210284669-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2021-09-16 | — | — | US | disclosed |
| US-20210284669-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | POLRMT 535/4885CYP3A4 435/4885CYP2C9 1982/4885 |
| US-20220356196-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | POLRMT 535/4885CYP3A4 435/4885CYP2C9 1982/4885 |
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | IRF3, IFNAR1, HAVCR2 | POLRMT 1073/4885CYP3A4 155/4885CYP2C9 1733/4885 |
| US-20210284670-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | POLRMT 535/4885CYP3A4 435/4885CYP2C9 1982/4885 |
| US-12264173-B2 | Antiviral compounds | MAVS, HAVCR2, ZC3HAV1 | POLRMT 535/4885CYP3A4 435/4885CYP2C9 1982/4885 |
| US-20210284669-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, SNRPA | POLRMT 352/4885CYP3A4 147/4885CYP2C9 530/4885 |
| US-11767337-B2 | Antiviral compounds | MAVS, HAVCR2, ZC3HAV1 | POLRMT 535/4885CYP3A4 435/4885CYP2C9 1982/4885 |
| US-20240174704-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | POLRMT 535/4885CYP3A4 435/4885CYP2C9 1982/4885 |
| US-12054507-B2 | Antiviral compounds | MAVS, HAVCR2, SNRPA | POLRMT 352/4885CYP3A4 147/4885CYP2C9 530/4885 |
| US-20250034186-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, SNRPA | POLRMT 259/4885CYP3A4 169/4885CYP2C9 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.